Episealer® health economy publication accepted for publication in Journal of ISAKOS
Episurf Medical (Nasdaq: EPIS B) today announces that results from a cost utility study, focusing on the health economic aspects of the treatment with the Episealer® knee implant, has been accepted for publication in the Journal of ISAKOS. The manuscript, with the title “Individualized metal implants for focal cartilage lesions in the knee can be cost effective: A simulation on 47-year-olds in a Swedish setting” by L. Bernfort et al. assesses the cost utility of a resurfacing knee implant for focal cartilage lesions compared with the biological treatment option microfracture, being the standard procedure in Sweden. The manuscript concludes that the Episealer® implant may be a cost-effective treatment alternative for patients in their 40s, when compared to microfracture.
“The article shows that treatment of patients in their 40s with cartilage lesions using the Episealer® not only helps the patients but also represents a favourable financial option from a health economic perspective. Up front, the Episealer® is more expensive than microfracture. Already after 5 years, however, the relative costs have decreased to an acceptable level and in the long term, initial treatment with the Episealer® is both more inexpensive and gives better clinical results than microfracture”, says Leif Ryd, Senior Medical Advisor Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 1 March 2023.
Tags: